181 registration certificates, or about half of the active portfolio of medicines of the Russian pharmaceutical company Binnopharm Group, have already been brought into compliance with the requirements of international treaties and instruments of the Eurasian Economic Union countries. The company’s portfolio includes a total of 450 registration certificates, the press service of Binnopharm Group reported.
“Our company has opened its representative offices in six CIS countries, three of them are open in the EAEU states – Armenia, Belarus and Kazakhstan. There are plans to open a representative office in Kyrgyzstan. We are expanding our presence in the EAEU countries, so our activities comply with all regulatory requirements established in the Union states,” commented Rustem Muratov, CEO of Binnopharm Group.
Medicines registered in accordance with the legislation of the member states must be brought into compliance with the requirements of international treaties and instruments of the Eurasian Economic Union by December 31, 2025, the company noted.
“According to the Research Center for the Expert Examination of Medical Devices of the Ministry of Health of the Russian Federation, currently more than 15,000 medicines have been registered in Russia, of which more than a thousand have been brought into compliance with the requirements of the EAEU, with about a fifth of them being products of the Binnopharm Group,” the press service added.
As it became known earlier, the revenue of Binnopharm Group increased in the first nine months of 2022 by 12.2%.
